These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

91 related articles for article (PubMed ID: 3837504)

  • 1. Continuous ambulatory EEG monitoring following desferrioxamine (DFO) i.v. infusion.
    Poignet JL; Monge MF; Ciancioni C; Mikol F; Naret C; Delons S; Man NK
    Trans Am Soc Artif Intern Organs; 1985; 31():546-51. PubMed ID: 3837504
    [No Abstract]   [Full Text] [Related]  

  • 2. Plasma aluminum and iron kinetics in hemodialyzed patients after i.v. infusion of desferrioxamine.
    Ciancioni C; Poignet JL; Mauras Y; Panthier G; Delons S; Allain P; Man NK
    Trans Am Soc Artif Intern Organs; 1984; 30():479-82. PubMed ID: 6533925
    [No Abstract]   [Full Text] [Related]  

  • 3. Desferrioxamine in the treatment of aluminum overload.
    Ackrill P; Day JP
    Clin Nephrol; 1985; 24 Suppl 1():S94-7. PubMed ID: 3842106
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Aluminum accumulation in children on chronic dialysis: predictive value of serum aluminum levels and desferrioxamine infusion test.
    Roodhooft AM; van de Vyver FL; D'Haese PC; van Acker KJ; Visser WJ; de Broe ME
    Clin Nephrol; 1987 Sep; 28(3):125-9. PubMed ID: 3665205
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of desferrioxamine infusion on red blood cell aluminum.
    Umeda M; Umimoto K; Tsurusaki K; Izumi N; Kishimoto T; Maekawa M
    ASAIO Trans; 1988; 34(3):297-9. PubMed ID: 3196524
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The role of desferrioxamine in dialysis-associated mucormycosis: report of three cases and review of the literature.
    Boelaert JR; van Roost GF; Vergauwe PL; Verbanck JJ; de Vroey C; Segaert MF
    Clin Nephrol; 1988 May; 29(5):261-6. PubMed ID: 3293856
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prevention and treatment of aluminum intoxication in chronic renal failure.
    Simon P; Allain P; Ang KS; Cam G; Mauras Y
    Adv Nephrol Necker Hosp; 1985; 14():439-78. PubMed ID: 3919543
    [No Abstract]   [Full Text] [Related]  

  • 8. Correlation between serum aluminum concentration and signs of encephalopathy in a large population of patients dialyzed with aluminum-free fluids.
    Rovelli E; Luciani L; Pagani C; Albonico C; Colleoni N; D'Amico G
    Clin Nephrol; 1988 Jun; 29(6):294-8. PubMed ID: 3396232
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Desferrioxamine infusion can modify EEG tracing in haemodialysed patients.
    Brancaccio D; Avanzini G; Padovese P; Gallieni M; Franceschetti S; Panzica F; Anelli A; Colantonio G; Martinelli D; Bugiani O
    Nephrol Dial Transplant; 1991; 6(4):264-8. PubMed ID: 1881580
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Successful treatment of progressive dialysis encephalopathy. Case report].
    Weiland P; Köhler M; Glatzel E
    Z Urol Nephrol; 1985 Jul; 78(7):387-93. PubMed ID: 4050157
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Severe ocular toxicity of desferrioxamine in the hemodialyzed patient].
    Bournerias F; Monnier N; Dufier JL; Réveillaud RJ
    Nephrologie; 1987; 8(1):27-9. PubMed ID: 3587485
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Use of a desferrioxamine "microdose" to chelate aluminum in hemodialysis patients.
    Jorge C; Gil C; Possante M; Catarino MC; Cruz A; Andrade R; Teixeira R; Santos N; Ferreira A
    Clin Nephrol; 1999 Nov; 52(5):335-6. PubMed ID: 10585000
    [No Abstract]   [Full Text] [Related]  

  • 13. Exacerbation of aluminium encephalopathy after treatment with desferrioxamine.
    Lillevang ST; Pedersen FB
    Nephrol Dial Transplant; 1989; 4(7):676. PubMed ID: 2510071
    [No Abstract]   [Full Text] [Related]  

  • 14. Desferrioxamine and hemofiltration for aluminum removal in patients on regular dialysis treatment.
    Segoloni G; Canavese G; D'Amicone M; Rubino GF; Scansetti G; Lamon S; Talarico S; Luda E; Vercellone A
    Clin Nephrol; 1983 Aug; 20(2):105-8. PubMed ID: 6616975
    [No Abstract]   [Full Text] [Related]  

  • 15. Role of desferrioxamine in the treatment of dialysis encephalopathy.
    Ackrill P; Ralston AJ; Day JP
    Kidney Int Suppl; 1986 Feb; 18():S104-7. PubMed ID: 3457985
    [No Abstract]   [Full Text] [Related]  

  • 16. Red blood cell aluminum in patients with renal failure and effect of desferrioxamine infusion.
    Umeda M; Tsurusaki K; Kamikawa S; Izumi N; Yasumoto R; Kishimoto T; Maekawa M
    Blood Purif; 1990; 8(5):295-300. PubMed ID: 2091689
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Changes of metal concentrations in blood and peritoneal dialysate during long-term desferrioxamine B therapy.
    Romero RA; Salgado O; Elejalde LE; Rodríguez-Iturbe B; Tahán JE
    Transplant Proc; 1996 Dec; 28(6):3385-7. PubMed ID: 8962321
    [No Abstract]   [Full Text] [Related]  

  • 18. Desferrioxamine-induced changes of aluminium kinetics during haemodialysis.
    Graf H; Stummvoll HK; Meisinger V
    Proc Eur Dial Transplant Assoc; 1981; 18():674-80. PubMed ID: 7329995
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of desferrioxamine on aluminum kinetics during hemodialysis.
    Stummvoll HK; Graf H; Meisinger V
    Miner Electrolyte Metab; 1984; 10(4):263-6. PubMed ID: 6749073
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Irreversible ocular toxicity from single "challenge" dose of deferoxamine.
    Bene C; Manzler A; Bene D; Kranias G
    Clin Nephrol; 1989 Jan; 31(1):45-8. PubMed ID: 2783668
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.